12:00 AM
 | 
Feb 21, 2013
 |  BC Innovations  |  Targets & Mechanisms

Huperzine A in SCI

Harvard Medical School researchers have shown that the plant-derived small molecule huperzine A can reduce neuropathic pain in rats with spinal cord injury.1Insero Health Inc. has licensed IP from Harvard covering the use of huperzine A to treat epilepsy and neuropathic pain and plans to report Phase Ib data this year in treatment-resistant epilepsy.

Neuropathic pain is one of the most frequent complications associated with spinal cord injury (SCI), occurring in at least 40% of patients.2 Because there are multiple pathways and mechanisms that underlie pain in SCI,3 the Harvard team hypothesized that a single compound with effects on those pathways might have a better chance of success than a compound against a single target.

To test that idea, the researchers chose to study huperzine A in a mouse model of SCI. Huperzine A is a small molecule alkaloid isolated from the Chinese club...

Read the full 720 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$85 USD
More Info >